Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method

被引:10
|
作者
Thariat, J. [1 ]
Ferrand, F. -R [2 ,3 ]
Fakhry, N. [4 ]
Even, C. [3 ]
Vergez, S. [5 ,6 ]
Chabrillac, E. [5 ]
Sarradin, V. [7 ]
Digue, L. [8 ]
Troussier, I. [9 ]
Bensadoun, R. -J [9 ]
机构
[1] Ctr Francois Baclesse, Dept Radiotherapie, Caen, France
[2] French Armed Forces Biomed Res Inst, F-91220 Bretigny Sur Orge, France
[3] Inst Gustave Roussy, Dept Oncol Med, Villejuif, France
[4] Aix Marseille Univ, Hop Conception, AP HM, Dept ORL & Chirurg Cervicofaciale, 147 Blvd Baille, BR-13005 Marseille, Brazil
[5] Inst Univ Canc Toulouse Oncopole, Dept Chirurg, Toulouse, France
[6] Univ Toulouse III Paul Sabatier, CHU Toulouse Larrey, Dept Chirurg ORL & Cervicofaciale, Toulouse, France
[7] Inst Univ Canc Toulouse Oncopole, Dept Oncol Med, Toulouse, France
[8] Hop St Andre, Dept Oncol Med, Bordeaux, France
[9] Ctr Haute Energie, Dept Oncol Radiotherapie, Nice, France
关键词
Salivary gland cancer; Radiotherapy; Hadrontherapy; ADENOID CYSTIC CARCINOMA; INTENSITY-MODULATED RADIOTHERAPY; CARBON-ION RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA; RADIATION-THERAPY IMRT; ADJUVANT RADIOTHERAPY; TREATMENT OUTCOMES; NECK-CANCER; HEAD; MULTICENTER;
D O I
10.1016/j.anorl.2023.11.006
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective: To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes.<br /> Material and methods: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.<br /> Results: Postoperatively, radiotherapy to the primary tumor site +/- to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk > 10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered.<br /> Conclusion: Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.<br /> (c) 2023 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:221 / 226
页数:6
相关论文
共 50 条
  • [1] Cytopathological analysis of salivary gland cancer: REFCOR recommendations by the formal consensus method
    Courtade-Saidi, M.
    Uro-Coste, E.
    Vergez, S.
    Verillaud, B.
    Dang, N. Pham
    Chabrillac, E.
    Fakhry, N.
    Bigorgne, C.
    Costes-Martineau, V.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (02) : 87 - 91
  • [2] Surgery of sublingual and minor salivary gland cancer: REFCOR recommendations by the formal consensus method
    Pham Dang, N.
    Jegoux, F.
    Barry, B.
    Verillaud, B.
    Baujat, B.
    Fakhry, N.
    Chabrillac, E.
    Vergez, S.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (06) : 335 - 338
  • [3] Lymph node surgery for salivary gland cancer: REFCOR recommendations by the formal consensus method
    Baujat, B.
    Vergez, S.
    Jegoux, F.
    Barry, B.
    Verillaud, B.
    Dang, N. Pham
    Fakhry, N.
    Chabrillac, E.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (04) : 215 - 220
  • [4] Post-treatment monitoring of salivary gland cancer: REFCOR recommendations by the formal consensus method
    Chabrillac, E.
    Vergez, S.
    Barry, B.
    Jegoux, F.
    Verillaud, B.
    Dang, N. Pham
    Baujat, B.
    Fakhry, N.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (06) : 339 - 341
  • [5] Surgery of major salivary gland cancers: REFCOR recommendations by the formal consensus method
    Barry, B.
    Verillaud, B.
    Jegoux, F.
    Dang, N. Pham
    Baujat, B.
    Chabrillac, E.
    Vergez, S.
    Fakhry, N.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (03) : 153 - 160
  • [6] Diagnostic imaging of salivary gland cancers: REFCOR recommendations by the formal consensus method
    Varoquaux, A.
    Fakhry, N.
    Baujat, B.
    Verillaud, B.
    Jegoux, F.
    Barry, B.
    Chabrillac, E.
    Vergez, S.
    Terroir-Cassou-Mounat, M.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (01) : 27 - 31
  • [7] Systemic therapies for salivary gland cancer: Adenoid cystic carcinoma. REFCOR recommendations by the formal consensus method
    Ferrand, F. -R.
    Even, C.
    Chabrillac, E.
    Thariat, J.
    Fakhry, N.
    Vergez, S.
    Bensadoun, R. -J.
    Sarradin, V.
    Digue, L.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (05) : 286 - 291
  • [8] Salivary gland cancer: Recommendations by formal consensus, for the French Network of Rare Head and Neck Tumors (REFCOR)
    Vergez, S.
    Chabrillac, E.
    Fakhry, N.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (01) : 3 - 4
  • [9] Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method
    Sarradin, V.
    Digue, L.
    Vergez, S.
    Thariat, J.
    Fakhry, N.
    Chabrillac, E.
    Bensadoun, R. -J
    Ferrand, F. -R
    Even, C.
    EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2024, 141 (05) : 280 - 285
  • [10] A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network)
    Cerda, Thomas
    Sun, Xu Shan
    Vignot, Stephane
    Marcy, Pierre-Yves
    Baujat, Bertrand
    Baglin, Anne-Catherine
    Ali, Ali Mohamed
    Testelin, Sylvie
    Reyt, Emile
    Janot, Francois
    Thariat, Juliette
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 91 (02) : 142 - 158